Theravance Biopharma (TBPH) Return on Capital Employed (2014 - 2026)

Theravance Biopharma (TBPH) has 13 years of Return on Capital Employed data on file, last reported at 0.3% in Q1 2026.

• Return on Capital Employed for Q1 2026 came in at 0.3%, up 1611.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 0.3% (up 1611.0% YoY), and the FY2025 annual result was 8.47%, up 2244.0% from the prior year.
• Return on Capital Employed grew to 0.3% in Q1 2026 per TBPH's latest filing, from 0.87% in the prior quarter.
• Over five years, Return on Capital Employed peaked at 0.3% in Q1 2026 and troughed at 66.19% in Q1 2022.
• A 5-year average of 18.44% and a median of 14.33% in 2023 frame the typical range for Return on Capital Employed.
• The sharpest annual moves came in 2022 and 2025: Return on Capital Employed soared 6403 bps in 2022, then tumbled 389 bps in 2025.
• A 5-year view of Return on Capital Employed shows it stood at 14.0% in 2022, then fell by 7 bps to 15.02% in 2023, then increased by 3 bps to 14.53% in 2024, then surged by 94 bps to 0.87% in 2025, then jumped by 135 bps to 0.3% in 2026.
• Business Quant data shows TBPH's Return on Capital Employed at 0.3% in Q1 2026, 0.87% in Q4 2025, and 8.56% in Q3 2025.